Clinical trials: ERBB2 Altered Breast Cancer
Metastatic Breast Cancer
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
The objective of this phase II study is to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five patients will be enrolled into this study.
- Trial name
- NCT01658033
- Testing
- Avastin + mFOLFOX6
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Breast Cancer
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
The aim of this study was to assess real-world treatment patterns and tolerability of ribociclib among patient populations historically underrepresented in clinical trials - specifically older adults and Black/African American…
- Trial name
- NCT07760714
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety…
- Trial name
- NCT00864175
- Testing
- INCB007839, trastuzumab, Docetaxel
- Where
- 12 sites in India
- Volunteers
- 68 people
- Sponsor
- Incyte Corporation
Breast Cancer Female
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of-care chemotherapy (followed by…
- Trial name
- ADAPTcycle (NCT04055493)
- Testing
- Ribociclib 200Mg Oral Tablet
- Where
- 86 sites in Germany
- Volunteers
- 1,684 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
This is an international, multicenter, open-label, non-comparative, Simon´s two-stage design, phase II clinical trial.
- Trial name
- DxCARTES (NCT03819010)
- Testing
- Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib, Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
- Where
- 18 sites in Portugal, Spain
- Volunteers
- 66 people
- Sponsor
- MedSIR
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients with PTEN-Altered advanced…
- Trial name
- NCT04997993
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Deborah Doroshow
Breast Cancer, HER-2 Positive Breast Cancer
Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer
Abemaciclib (Verzenio) is a commonly used treatment for hormone receptor-positive breast cancer, but it can cause gastrointestinal side effects such as diarrhea, which may affect quality of life and treatment tolerance.
- Trial name
- MICRO-VERZ (NCT07406594)
- Testing
- Resistant Potato Starch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Vermont Medical Center
Solid Tumor, Gastric Cancer
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT04511871
- Testing
- CCT303-406
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Breast Cancer
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
- Trial name
- NCT03123263
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Breast Cancer, HER2-negative Breast Cancer
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Trial name
- NCT04504331
- Testing
- Infigratinib, Tamoxifen, Omnipaque 350
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jennifer Lee Caswell-Jin
HER2 Positive Breast Cancer
Adapted Physical Activity for Breast Cancer HER2 Positive Patient
The purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for HER2+ breast cancer.
- Trial name
- APACAN2 (NCT02963363)
- Testing
- Home-based Adapted Physical Activity
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Jean Perrin
HER2-negative Breast Cancer
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
- Trial name
- NeoHTerMa (NCT05889390)
- Testing
- Oncotherm EHY-2030, Paclitaxel, Carboplatin
- Where
- Hungary
- Volunteers
- 71 people
- Sponsor
- Semmelweis University
Breast Cancer
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
This randomized study will assess the effect of adding bevacizumab to trastuzumab plus docetaxel in neoadjuvant therapy in participants with early stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
- Trial name
- AVATAXHER (NCT01142778)
- Testing
- Bevacizumab, Docetaxel, Trastuzumab
- Where
- 28 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
This study aims to address the following key objectives in patients with HER2-altered mBC: Primary objectives Estimate the prevalence of human epidermal growth factor receptor 2 positive (HER2+), human epidermal growth factor…
- Trial name
- NCT07342309
- Where
- United States
- Volunteers
- 7,933 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Breast Cancer, Neoadjuvant Therapy
Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China
Prognostic assessment after preoperative systemic therapy (PST) plays a vital role in breast cancer patients. The clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease and nuclear grade 3 tumor…
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Neoplasm Staging, Estrogen Receptor
- Trial name
- NCT03437837
- Where
- 12 sites in China
- Volunteers
- 1,077 people
- Sponsor
- Peking University First Hospital
HER2-negative Breast Cancer, ER Positive Breast Cancer
D4 Choline Breast PET/CT
The aim of this study is to evaluate the effect of CDK4/6 inhibitor treatment on the tumour choline metabolism as determined by [18F]D4-FCH PET/ computed tomography(CT) in breast cancer and to determine the suitability of…
- Conditions
- HER2-negative Breast Cancer, ER Positive Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT04276272
- Testing
- Imaging scan
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Breast Cancer
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
The current trial, BNIT-BR-002, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2, with and without Herceptin, following 1st- or 2nd-line chemotherapy in patients with Her-2-positive metastatic…
- Trial name
- NCT00485277
- Testing
- MVA-BN-HER2
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bavarian Nordic
Breast Cancer, Advanced Breast Cancer
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- SABINA (NCT05810870)
- Testing
- MEN1611, Eribulin
- Where
- 13 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR